ReviewFrontiers in immunology2021
Reprogramming Immune Cells for Enhanced Cancer Immunotherapy: Targets and Strategies.
Review in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A Large-Scale Meta-Analysis Reveals Positive Feedback between Macrophages and T Cells That Sensitizes Tumors to Immunotherapy.Cancer research · 2024Pooled it
- Mechanisms of lactylation modification in hepatocellular carcinoma treatment resistance.Gastroenterology report · 2026Review
- Identification of cancer-associated fibroblast subpopulation and construction of an immunotherapy signature for gastric cancer.Translational cancer research · 2025Article
- Molecular and immunological determinants of long-term survival in multiple myeloma.Blood advances · 2025Review
- Clinical potential of CAR T cell-derived extracellular vesicles (CAR-EVs) in cancer therapy: a cell-free approach.Therapeutic delivery · 2025Review
- [Preparation of Trop2-Targeted CAR-T Cells Based on Nanobodies and Their Antitumor Effects Against Non-Small Cell Lung Cancer].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2025Article
- Machine learning-based screening and validation of liver metastasis-specific genes in colorectal cancer.Scientific reports · 2024Article
- Review
- Finding potential targets in cell-based immunotherapy for handling the challenges of acute myeloid leukemia.Frontiers in immunology · 2024Review
- Reversing NK cell exhaustion: a novel strategy combining immune checkpoint blockade with drug sensitivity enhancement in the treatment of hepatocellular carcinoma.Frontiers in oncology · 2024Review
- Article
- A neutrophil mimicking metal-porphyrin-based nanodevice loaded with porcine pancreatic elastase for cancer therapy.Nature communications · 2023Article
- Reprogramming the tumor microenvironment with biotechnology.Biomaterials research · 2023Review
- The roles of inflammasomes in cancer.Frontiers in immunology · 2023Review
- Nanobodies in cell-mediated immunotherapy: On the road to fight cancer.Frontiers in immunology · 2023Review
- Identification of a necroptosis-related gene signature as a novel prognostic biomarker of cholangiocarcinoma.Frontiers in immunology · 2023Article
- Contrast subgraphs allow comparing homogeneous and heterogeneous networks derived from omics data.GigaScience · 2022Article
- Targeting of the tumor immune microenvironment by metformin.Journal of cell communication and signaling · 2022Review
- Irradiation immunity interactions.Journal of medical imaging and radiation oncology · 2022Review
- T Lymphocyte and CAR-T Cell-Derived Extracellular Vesicles and Their Applications in Cancer Therapy.Cells · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is one of the leading causes of death and a major public health problem all over the world. Immunotherapy is becoming a revolutionary clinical management for various cancer types. Restoration of aberrant immune surveillance on cancers has achieved markable progress in the past years by either
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.